Skip to content

Clinical trials

Observational Schizophrenia trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Schizophrenia Phase: Observational Country / region: Canada Clear all

30 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20041
20061
20082
20114
20121
20142
20151
20162
20182
20193
20212
20232
20243
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed10
Unknown status6
Active, not recruiting4
Recruiting4
Terminated3
Not yet recruiting2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Centre for Addiction and Mental Health6
Douglas Mental Health University Institute3
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's3
The Royal Ottawa Mental Health Centre2
University of British Columbia2
BC Mental Health and Addictions Research Institute1
Canadian Network for Observational Drug Effect Studies, CNODES1
Daniel Benjamin1
Fraser Health1
Hoffmann-La Roche1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Schizophrenia30
Psychotic Disorders19
Bipolar Disorder3
Diabetes Mellitus3
Anxiety Disorders2
Language Disorders2
Adenoviridae Infections1
Alcoholism1
Arrhythmias, Cardiac1
Autistic Disorder1

Trials

Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.